Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2

Annals of Internal Medicine(2021)10.7326/m21-1757Source: DataRank Database

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 is a research paper published in Annals of Internal Medicine (2021). On theSindex it has a DataRank of 0. It has been cited 321 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access321 citations

Free full text

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)OA: greenTopics (3)Linked Datasets (12)DataCite Reuse (12)IDs (PubMed)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (40)

Wooseob Kim ORCID,Michael Paley ORCID,Monica Yang ORCID,Alexander Carvidi,Emanuel Demissie

Live enrichment

PubMed:21097893

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: P30AR073752

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: P30AR070155

National Institute of Diabetes and Digestive and Kidney Diseases

Grant: P30DK052574

National Cancer Institute

Grant: P30CA091842

National Institute of Allergy and Infectious Diseases

Grant: 75N93019C00051

National Center for Advancing Translational Sciences

Grant: UL1TR002345

National Institutes of Health

Grant: 1P30DK052574-01A1

Core--Transgenic mouse and stem cell

National Institutes of Health

Grant: 5R01NS106289-04

The Role of TRPV4 in central nervous system immunity and disease

National Institutes of Health

Grant: 5P30AR073752-02

Washington University Rheumatic DiseasesResearch Resource-based Center

National Institutes of Health

Grant: 5P30AR070155-02

Resource-based Center for the Advancement of Precision Medicine in Rheumatology

National Institutes of Health

Grant: 5R01DK109384-04

TARGETING TRYPTOPHAN METABOLISM IN COLITIS ASSOCIATED CANCER

National Institutes of Health

Grant: 2U01AI141990-06

Programming Durable Immune Responses To Vaccination

National Institutes of Health

Grant: 1UL1TR002345-01

Washington University Institute of Clinical and Translational Sciences

National Institutes of Health

Grant: 5P30CA091842-05

Core--Pharmacology Facility

green

repositoryhttps://escholarship.org/uc/item/9f21p0fx

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8407518

https://doi.org/10.7326/m21-1757

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8407518

https://pubmed.ncbi.nlm.nih.gov/34461029

Fields of Study

0301 basic medicine03 medical and health sciences0302 clinical medicine

Sustainable Development Goals

SDG 3: 3. Good healthSDG 16: 16. Peace & justice

Additional file 1 of The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

10.6084/m9.figshare.21285737.v1figshare

Additional file 1 of The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

10.6084/m9.figshare.21285737figshare

Additional file 1 of Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy

10.6084/m9.figshare.26605015.v1figshare

10.6084/m9.figshare.26605015figshare

Additional file 2 of Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy

10.6084/m9.figshare.26605018.v1figshare

10.6084/m9.figshare.26605018figshare

Additional file 3 of Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy

10.6084/m9.figshare.26605021.v1figshare

10.6084/m9.figshare.26605021figshare

Additional file 1 of Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases

10.6084/m9.figshare.26663110.v1figshare

Additional file 2 of Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases

10.6084/m9.figshare.26663113.v1figshare

Additional file 1 of Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases

10.6084/m9.figshare.26663110figshare

Additional file 2 of Biological and glucocorticoids treatment impair the medium-term immunogenicity to SARS-CoV-2 mRNA vaccines in autoimmune inflammatory rheumatic diseases

10.6084/m9.figshare.26663113figshare